H. Lundbeck A/S (HLUBF)
| Market Cap | 6.82B +8.7% |
| Revenue (ttm) | 3.97B +10.4% |
| Net Income | 601.31M +14.7% |
| EPS | 0.61 +14.7% |
| Shares Out | n/a |
| PE Ratio | 11.34 |
| Forward PE | 7.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 120 |
| Open | 6.56 |
| Previous Close | 5.54 |
| Day's Range | 6.56 - 6.56 |
| 52-Week Range | 4.82 - 6.56 |
| Beta | 0.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About H. Lundbeck
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati... [Read more]
Financial Performance
In 2025, H. Lundbeck's revenue was 24.63 billion, an increase of 11.93% compared to the previous year's 22.00 billion. Earnings were 3.19 billion, an increase of 1.56%.
Financial numbers in DKK Financial StatementsNews
The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome
The U.S. FDA has granted Orphan Drug Designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of endogenous Cushing's syndrome Endogeno...
H. Lundbeck Quarterly report: Q2 2026
H. Lundbeck has published its Q2 2026 quarterly earnings report on August 21, 2026.
H. Lundbeck Slides: Q2 2026
H. Lundbeck has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 21, 2026.
H. Lundbeck Earnings Call Transcript: Q2 2026
Strong H1 2026 results with 16% revenue growth and robust performance from VYEPTI and REXULTI. Guidance for the full year is maintained, with expectations to trend towards the upper end, supported by a strengthened pipeline and disciplined capital allocation.
H. Lundbeck Quarterly report: Q2 2026
H. Lundbeck has published its Q2 2026 quarterly earnings report on August 19, 2026.
H. Lundbeck Slides: Q2 2026
H. Lundbeck has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 19, 2026.
Lundbeck sees no slowdown in key drugs despite cautious 2026 outlook, CEO says
H. Lundbeck sees no slowdown in demand for its two main growth drugs, its chief executive said on Wednesday, after the Danish drugmaker reiterated its full-year outlook despite stronger-than-expecte...
Lundbeckfond Invest A/S launches voluntary exchange offer for A-shares in H. Lundbeck A/S
VALBY, Denmark, Aug. 19, 2026 /PRNewswire/ -- H. Lundbeck A/S ("Lundbeck") hereby informs that Lundbeckfond Invest A/S ("Lundbeckfond Invest"), a fully owned subsidiary of the Lundbeck Foundation and ...
Tarek Samad appointed EVP, Head of Research & Development at Lundbeck
VALBY, Denmark, June 24, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head of Research & Development (R&D) and will ...
Lundbeck drug candidate shows promise in Cushing's disease trial
Danish drugmaker H. Lundbeck said on Sunday its investigational drug asedebart showed encouraging tolerability and results in a small mid-stage study for the treatment of Cushing's disease, a rare ho...
H. Lundbeck Transcript: Study update
Bocunebart, a first-in-class anti-PACAP biologic, showed significant efficacy and a clean safety profile in the phase II-B PROCEED trial for chronic migraine patients with prior treatment failures. The drug achieved a 2.3-day greater reduction in monthly migraine days versus placebo and is positioned to address unmet needs in severe migraine, with phase III planning underway.
H. Lundbeck Press release: Study update
H. Lundbeck issued a press release on June 5, 2026, disclosing material business information to investors.
H. Lundbeck Slides: Study update
H. Lundbeck has posted slides in relation to its latest quarterly earnings report, which was published on June 5, 2026.
Lundbeck's experimental drug cuts migraine days in mid-stage trial
Denmark's Lundbeck said on Thursday its experimental drug bocunebart cut monthly migraine days in a mid-stage study, supporting further development of a new type of treatment for migraine, one of th...
H. Lundbeck Quarterly report: Q1 2026
H. Lundbeck has published its Q1 2026 quarterly earnings report on May 13, 2026.
H. Lundbeck Slides: Q1 2026
H. Lundbeck has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
H. Lundbeck Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue and profit growth, driven by VYEPTI and REXULTI, successful partner market transitions, and pipeline progress. Upgraded guidance reflects robust fundamentals, with continued investment in innovation and disciplined capital allocation.
H. Lundbeck Quarterly report: Q1 2026
H. Lundbeck has published its Q1 2026 quarterly earnings report on May 13, 2026.
H. Lundbeck Slides: Q1 2026
H. Lundbeck has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
H. Lundbeck Slides: Investor update
H. Lundbeck has posted slides in relation to its latest quarterly earnings report, which was published on April 9, 2026.
H. Lundbeck Transcript: AGM 2026
Record revenues and profitability were achieved in 2025, with strong growth in strategic brands and a robust pipeline. The board and executive team were re-elected, a new member with neuroscience expertise joined, and all proposals—including a 21% dividend increase—were approved.
H. Lundbeck Slides: FY 2026
H. Lundbeck has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 18, 2026.
Lundbeck price target lowered to DKK 40 from DKK 44 at Deutsche Bank
Deutsche Bank analyst Niall Alexander lowered the firm’s price target on Lundbeck (HLBBF) to DKK 40 from DKK 44 and keeps a Hold rating on the shares. Published first on…
H. Lundbeck Annual report: Q4 2025
H. Lundbeck has published its Q4 2025 annual report on February 4, 2026.
H. Lundbeck Quarterly report: Q4 2025
H. Lundbeck has published its Q4 2025 quarterly earnings report on February 4, 2026.